share_log

Why Is Penny Stock Clearmind Gaining Today?

Why Is Penny Stock Clearmind Gaining Today?

爲什麼便士股票Clearmind今天在上漲?
Benzinga ·  12/24 17:32

Clearmind Medicine Inc. (NASDAQ:CMND) saw its shares rise on Tuesday after announcing that it has received Institutional Review Board (IRB) approval for its Phase I/IIa clinical trial of CMND-100, a drug targeting alcohol use disorder (AUD).

Clearmind Medicine Inc. (納斯達克:CMND) 在週二宣佈獲得了機構審查委員會(IRB)對其CMND-100的I/IIa期臨牀試驗的批准後,其股份上漲。

This approval marks a significant milestone in the company's FDA-regulated clinical program, and the trial will be conducted at Yale School of Medicine's Department of Psychiatry, led by Anahita Bassir Nia, an expert in psychiatry and addiction medicine.

這項批准標誌着該公司在FDA監管的臨牀項目中的一個重要里程碑,試驗將在耶魯醫學院精神病學系進行,由精神病學和成癮醫學專家Anahita Bassir Nia領導。

The trial will evaluate the safety, tolerability, and efficacy of CMND-100, a proprietary investigational drug designed to reduce alcohol cravings and consumption in individuals with moderate to severe AUD.

該試驗將評估CMND-100的安全性、耐受性和有效性,這是一種旨在減少中度至重度AUD患者的酒精渴求和消費的專有研究藥物。

Adi Zuloff-Shani, CEO of Clearmind Medicine, emphasized the importance of this step, noting that alcohol use is a leading preventable cause of death globally, responsible for 2.6 million deaths annually.

Clearmind Medicine的首席執行官Adi Zuloff-Shani強調了這一步的重要性,並指出,酗酒是全球主要的可預防死亡原因,每年導致260萬人的死亡。

Also Read: What's Going On With NIO Stock On Tuesday?

另請閱讀:週二NIO股票發生了什麼?

Current treatment options are limited, with low efficacy and patient compliance.

目前的治療選項有限,有效性低且患者依從性差。

Clearmind aims to address this gap with CMND-100, offering a potential solution for treating AUD that could significantly improve patient outcomes.

Clearmind旨在通過CMND-100填補這一空白,提供治療AUD的潛在解決方案,可能顯著改善患者的治療效果。

The trial is expected to provide critical data to support the advancement of CMND-100 through its clinical pipeline, offering hope for more effective treatment options for those struggling with alcohol addiction.

該試驗預計將提供關鍵數據,以支持CMND-100在其臨牀管道中的推進,爲那些與酗酒鬥爭的人們提供更有效治療選擇的希望。

According to Benzinga Pro, CMND stock has lost over 6% in the past month. Investors can gain exposure to the stock via AdvisorShares Psychedelics ETF (NYSE:PSIL).

根據Benzinga Pro,CMND股票在過去一個月中下跌了超過6%。投資者可以通過AdvisorShares Psychedelics可交易ETF(紐交所:PSIL)來獲得該股票的投資機會。

Price Action: CMND shares are trading higher by 35% to $1.64 at last check Tuesday.

價格走勢:截至週二最後一次檢查,CMND股票上漲了35%,交易價格爲1.64美元。

Read Action:

閱讀動態:

  • Bitcoin Flat, Ethereum, Dogecoin Spike Ahead Of Christmas: Analyst Says Decline In BTC Dominance Leaves 'Room For Altcoins To Pick Up'
  • 比特幣平穩, 以太幣和狗狗幣在聖誕節前飆升:分析師表示比特幣主導地位下降爲其他幣種提供了"上升空間"

Photo: Shutterstock

Photo: Shutterstock

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論